Korro Bio (KRRO) Net Cash Flow (2018 - 2026)
Korro Bio's (KRRO) quarterly Net Cash Flow came in at $39.9 million in Q1 2026, up 369.33% YoY from $8.5 million in Q1 2025, and up 1758.27% on a QoQ basis from -$2.4 million in Q4 2025.
Korro Bio (KRRO) Net Cash Flow (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Net Cash Flow data on file, last reported at $39.9 million in Q1 2026.
- Quarterly Net Cash Flow rose 369.33% year-over-year to $39.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.5 million (up 96.82% YoY) and the FY2025 annual result came in at -$33.9 million, up 70.3% from the prior year.
- Net Cash Flow improved to $39.9 million in Q1 2026, from -$2.4 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $121.8 million in Q4 2023 to a low of -$49.4 million in Q2 2024.
- A 5-year average of -$1.1 million and a median of -$9.3 million in 2024 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 1897.37% in 2023, down 996.81% in 2023.
- Tracing KRRO's Net Cash Flow over 5 years: stood at -$6.8 million in 2022, then jumped by 1897.37% to $121.8 million in 2023, then plunged by 107.66% to -$9.3 million in 2024, then soared by 74.21% to -$2.4 million in 2025, then soared by 1758.27% to $39.9 million in 2026.
- The last three Net Cash Flow figures came in at $39.9 million (Q1 2026), -$2.4 million (Q4 2025), and -$9.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - | -37.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.81 Mn |
| Jun 30, 2026 | -37.81 Mn |
| Mar 31, 2026 | 39.90 Mn |
| Mar 31, 2026 | 39.90 Mn |
| Dec 31, 2025 | -2.41 Mn |
| Dec 31, 2025 | -2.41 Mn |
| Sep 30, 2025 | -9.46 Mn |
| Sep 30, 2025 | -9.46 Mn |
| Jun 30, 2025 | -30.52 Mn |
| Jun 30, 2025 | -30.52 Mn |
| Mar 31, 2025 | 8.50 Mn |
| Mar 31, 2025 | 8.50 Mn |
| Dec 31, 2024 | -9.33 Mn |
| Dec 31, 2024 | -9.33 Mn |
| Sep 30, 2024 | -27.95 Mn |
| Sep 30, 2024 | -27.95 Mn |
| Jun 30, 2024 | -49.43 Mn |
| Jun 30, 2024 | -49.43 Mn |
| Mar 31, 2024 | -27.36 Mn |
| Mar 31, 2024 | -27.36 Mn |